Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis

ABSTRACTMultiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and f...

Full description

Bibliographic Details
Main Authors: Dorota Kujawa, Lukasz Laczmanski, Slawomir Budrewicz, Anna Pokryszko-Dragan, Maria Podbielska
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Gut Microbes
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19490976.2023.2274126
_version_ 1797320555483889664
author Dorota Kujawa
Lukasz Laczmanski
Slawomir Budrewicz
Anna Pokryszko-Dragan
Maria Podbielska
author_facet Dorota Kujawa
Lukasz Laczmanski
Slawomir Budrewicz
Anna Pokryszko-Dragan
Maria Podbielska
author_sort Dorota Kujawa
collection DOAJ
description ABSTRACTMultiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and function of the gut microbiota. In this review, current experimental and clinical evidence is presented for the characteristics of gut dysbiosis found in MS, as well as for its relevant links with the course of the disease and the dysregulated immune response and metabolic pathways involved in MS pathology. Furthermore, therapeutic implications of these investigations are discussed, with a range of pharmacological, dietary and other interventions targeted at the gut microbiome and thus intended to have beneficial effects on the course of MS.
first_indexed 2024-03-08T04:40:51Z
format Article
id doaj.art-5fa345507d8545bdbe1c2672657e13e2
institution Directory Open Access Journal
issn 1949-0976
1949-0984
language English
last_indexed 2024-03-08T04:40:51Z
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series Gut Microbes
spelling doaj.art-5fa345507d8545bdbe1c2672657e13e22024-02-08T12:02:07ZengTaylor & Francis GroupGut Microbes1949-09761949-09842023-12-0115210.1080/19490976.2023.2274126Targeting gut microbiota: new therapeutic opportunities in multiple sclerosisDorota Kujawa0Lukasz Laczmanski1Slawomir Budrewicz2Anna Pokryszko-Dragan3Maria Podbielska4Laboratory of Genomics & Bioinformatics, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, PolandLaboratory of Genomics & Bioinformatics, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, PolandDepartment of Neurology, Wroclaw Medical University, Wroclaw, PolandDepartment of Neurology, Wroclaw Medical University, Wroclaw, PolandLaboratory of Microbiome Immunobiology, Ludwik Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Wroclaw, PolandABSTRACTMultiple sclerosis (MS) causes long-lasting, multifocal damage to the central nervous system. The complex background of MS is associated with autoimmune inflammation and neurodegeneration processes, and is potentially affected by many contributing factors, including altered composition and function of the gut microbiota. In this review, current experimental and clinical evidence is presented for the characteristics of gut dysbiosis found in MS, as well as for its relevant links with the course of the disease and the dysregulated immune response and metabolic pathways involved in MS pathology. Furthermore, therapeutic implications of these investigations are discussed, with a range of pharmacological, dietary and other interventions targeted at the gut microbiome and thus intended to have beneficial effects on the course of MS.https://www.tandfonline.com/doi/10.1080/19490976.2023.2274126Antibioticsdietdisease-modifying treatmentfecal microbiota transplantationgut microbiomemicrobiota
spellingShingle Dorota Kujawa
Lukasz Laczmanski
Slawomir Budrewicz
Anna Pokryszko-Dragan
Maria Podbielska
Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
Gut Microbes
Antibiotics
diet
disease-modifying treatment
fecal microbiota transplantation
gut microbiome
microbiota
title Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
title_full Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
title_fullStr Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
title_full_unstemmed Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
title_short Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
title_sort targeting gut microbiota new therapeutic opportunities in multiple sclerosis
topic Antibiotics
diet
disease-modifying treatment
fecal microbiota transplantation
gut microbiome
microbiota
url https://www.tandfonline.com/doi/10.1080/19490976.2023.2274126
work_keys_str_mv AT dorotakujawa targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis
AT lukaszlaczmanski targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis
AT slawomirbudrewicz targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis
AT annapokryszkodragan targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis
AT mariapodbielska targetinggutmicrobiotanewtherapeuticopportunitiesinmultiplesclerosis